Organon & Co. (OGN) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Organon & Co.'s filing signal turned negative.

Organon & Co. is a global healthcare company focused on delivering impactful medicines and solutions, with a portfolio of over 70 products primarily in women's health and general medicines, including biosimilars. The company operates in over 140 countries and territories, selling products through wholesalers, retailers, hospitals, government agencies, and managed healthcare providers. Organon's women's health portfolio includes contraception and fertility treatments, while its general medicines segment features biosimilars for immunology and oncology, alongside established brands in cardiovascular, respiratory, dermatology, and pain management. The company aims to address health needs that uniquely, disproportionately, or differently affect women, while also expanding access to essential treatments.

Revenue is driven by sales of its women's health products, particularly in contraception and fertility, and its general medicines portfolio, which includes biosimilars and established brands across various therapeutic areas like cardiovascular, respiratory, dermatology, and pain management.